Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.85 +10.7%	$2.68	$2.07 ▼ $4.20	$91.83M	0.43	90,446 shs	318,854 shs
GALT Galectin Therapeutics	$1.29 -1.8%	$1.34	$0.73 ▼ $3.17	$81.46M	0.62	318,569 shs	169,882 shs
IMAB I-Mab	$1.29 -1.5%	$0.87	$0.60 ▼ $2.00	$105.34M	1.13	316,679 shs	216,592 shs
OVID Ovid Therapeutics	$0.29 +6.5%	$0.30	$0.24 ▼ $3.31	$20.62M	0.27	481,289 shs	576,860 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	0.00%	+2.80%	-7.55%	-9.51%	+5.76%
GALT Galectin Therapeutics	0.00%	+2.34%	-5.76%	-12.08%	-51.84%
IMAB I-Mab	0.00%	+31.31%	+37.16%	+40.68%	-21.69%
OVID Ovid Therapeutics	0.00%	-1.86%	-13.47%	-43.24%	-90.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	1.8472 of 5 stars	3.6	2.0	0.0	1.8	1.7	0.0
GALT Galectin Therapeutics	1.2549 of 5 stars	3.0	0.0	0.0	3.3	1.7	0.0
IMAB I-Mab	2.5594 of 5 stars	3.7	3.0	0.0	2.0	1.7	0.6
OVID Ovid Therapeutics	3.9646 of 5 stars	3.5	2.0	4.6	1.4	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.25	Buy	$9.00	216.34% Upside
GALT Galectin Therapeutics	2.00	Hold	$11.00	754.70% Upside
IMAB I-Mab	3.33	Buy	$5.50	326.36% Upside
OVID Ovid Therapeutics	3.00	Buy	$2.78	859.77% Upside

Current Analyst Ratings Breakdown

Latest OVID, GALT, IMAB, and ANIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
4/24/2025	OVID Ovid Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/4/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
4/4/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00
4/2/2025	GALT Galectin Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
3/26/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/25/2025	ANIX Anixa Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/24/2025	OVID Ovid Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
3/21/2025	ANIX Anixa Biosciences	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	$210K	436.19	N/A	N/A	$0.59 per share	4.82
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	($1.01) per share	N/A
IMAB I-Mab	$3.27M	32.19	N/A	N/A	$2.93 per share	0.44
OVID Ovid Therapeutics	$548K	37.63	N/A	N/A	$1.24 per share	0.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-58.55%	-53.29%	6/3/2025 (Estimated)
GALT Galectin Therapeutics	-$41.07M	-$0.72	N/A	N/A	N/A	N/A	N/A	-163.15%	8/11/2025 (Estimated)
IMAB I-Mab	-$206.44M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	-$52.34M	-$0.35	N/A	N/A	N/A	-5,142.56%	-39.24%	-26.19%	8/12/2025 (Estimated)

Latest OVID, GALT, IMAB, and ANIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
5/15/2025	Q1 2025	GALT Galectin Therapeutics	-$0.20	-$0.15	+$0.05	-$0.15	N/A	N/A
5/13/2025	Q1 2025	OVID Ovid Therapeutics	-$0.14	-$0.14	N/A	-$0.14	$0.03 million	$0.13 million
3/31/2025	Q4 2024	GALT Galectin Therapeutics	-$0.16	-$0.19	-$0.03	-$0.19	N/A	N/A
3/11/2025	Q1 2025	ANIX Anixa Biosciences	-$0.10	-$0.10	N/A	-$0.10	N/A	N/A
3/11/2025	Q4 2024	OVID Ovid Therapeutics	-$0.16	-$0.13	+$0.03	-$0.13	$0.19 million	$0.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
GALT Galectin Therapeutics	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.54	8.54
GALT Galectin Therapeutics	N/A	1.13	1.13
IMAB I-Mab	N/A	15.99	15.99
OVID Ovid Therapeutics	0.18	5.66	5.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
GALT Galectin Therapeutics	11.68%
IMAB I-Mab	38.38%
OVID Ovid Therapeutics	72.24%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
GALT Galectin Therapeutics	50.10%
IMAB I-Mab	22.10%
OVID Ovid Therapeutics	13.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.20 million	24.05 million	Optionable
GALT Galectin Therapeutics	9	63.29 million	31.32 million	Optionable
IMAB I-Mab	380	81.66 million	63.49 million	Optionable
OVID Ovid Therapeutics	60	71.11 million	61.57 million	Optionable

OVID, GALT, IMAB, and ANIX Headlines

Recent News About These Companies

Q2 EPS Forecast for Ovid Therapeutics Decreased by Analyst

May 30 at 1:18 AM | americanbankingnews.com

HC Wainwright Issues Pessimistic Forecast for Ovid Therapeutics (NASDAQ:OVID) Stock Price

May 29, 2025 | americanbankingnews.com

Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates

May 13, 2025 | zacks.com

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

May 8, 2025 | cambridgenetwork.co.uk

Ovid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

May 6, 2025 | zacks.com

Ovid Police Chief, city accused of civil rights violations

April 24, 2025 | msn.com

Ovid Therapeutics (OVID) Receives a Buy from TD Cowen

April 23, 2025 | theglobeandmail.com

Biotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA Cuts

April 10, 2025 | biospace.com

Ovid's Main Street Business Owners Are Speaking Out About Recovery Process After January Fire

April 5, 2025 | weny.com

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

April 2, 2025 | markets.businessinsider.com

Nozzolio and NextEra to visit Ovid for donation event after Main Street fire

April 2, 2025 | fingerlakes1.com

Ovid Therapeutics price target lowered to $2 from $3 at H.C. Wainwright

March 25, 2025 | markets.businessinsider.com

Ovid Therapeutics price target lowered to $4 from $5 at BTIG

March 25, 2025 | markets.businessinsider.com

Ovid man arrested for failing to register as sex offender

March 21, 2025 | fingerlakes1.com

Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

March 12, 2025 | finance.yahoo.com

William Blair Sticks to Their Buy Rating for Ovid Therapeutics (OVID)

March 12, 2025 | markets.businessinsider.com

Ovid Therapeutics price target lowered to $3 from $4 at Wedbush

March 12, 2025 | markets.businessinsider.com

We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate

March 11, 2025 | uk.finance.yahoo.com

Ovid Therapeutics sees cash runway into 2H26

March 11, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Top 4 ETFs for China Exposure After Tariff Relief
By Nathan Reiff | May 17, 2025
View Top 4 ETFs for China Exposure After Tariff Relief
These ETFs Provide Easy Exposure to Growing International Markets
By Nathan Reiff | May 24, 2025
View These ETFs Provide Easy Exposure to Growing International Markets
Build a Complete Bond Portfolio With These 4 ETFs
By Nathan Reiff | May 17, 2025
View Build a Complete Bond Portfolio With These 4 ETFs
3 AI ETFs Tapping Into the Heart of the AI Revolution
By Chris Markoch | May 14, 2025
View 3 AI ETFs Tapping Into the Heart of the AI Revolution

OVID, GALT, IMAB, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.84 +0.28 (+10.70%)

Closing price 03:59 PM Eastern

Extended Trading

$2.87 +0.03 (+1.02%)

As of 04:01 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Galectin Therapeutics NASDAQ:GALT

$1.28 -0.03 (-1.91%)

As of 04:00 PM Eastern

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

I-Mab NASDAQ:IMAB

$1.29 -0.02 (-1.53%)

As of 04:00 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Ovid Therapeutics NASDAQ:OVID

$0.29 +0.02 (+6.54%)

As of 04:00 PM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time